DEFA14A: Know Labs Adjourns Special Stockholders Meeting to Allow More Voting Time

Know Labs, Inc. has adjourned its Special Meeting of Stockholders to July 31, 2025, to provide additional time for stockholders to vote on all proposals.

Summary

• The Special Meeting of Stockholders, originally scheduled for July 24, 2025, was adjourned to allow stockholders additional time to vote on proposals.
• The meeting will be reconvened at 1:30 p.m. Pacific Time on Thursday, July 31, 2025, at www.virtualshareholdermeeting.com/KNW2025SM.
• The record date for the reconvened Special Meeting remains June 20, 2025.
• The Board of Directors recommends that stockholders who have not yet voted cast their vote FOR each proposal.
• Stockholders who have already voted do not need to take further action unless they wish to change or revoke their prior vote.
• Voting can be done over the Internet (www.proxyvote.com), by telephone (1-800-690-6903), or by following instructions in the Notice received on or after July 1, 2025.
• Internet and telephone voting facilities will close at 11:59 p.m. Eastern time on July 30, 2025.
• Know Labs, Inc. is a technology innovator specializing in non-invasive health monitoring solutions, trading on the NYSE American Exchange under KNW.
• The company's patented and patent-pending spectroscopy technology identifies and monitors molecular signatures, enabling non-invasive testing.
• The first application of this technology will be a non-invasive glucose monitor, which requires U.S. Food and Drug Administration (FDA) clearance prior to market introduction.

Sentiment

Score: 5

Explanation: The filing is largely procedural, announcing the adjournment and rescheduling of a stockholder meeting. While the adjournment itself could be seen as a slight negative (indicating insufficient votes or engagement), the underlying business description of non-invasive health monitoring is positive. The risks section is standard for forward-looking statements, leading to a neutral overall sentiment.

Positives

• The company is a technology innovator specializing in non-invasive health monitoring solutions, addressing a significant market need.
• Know Labs possesses patented and patent-pending technology that uses spectroscopy to identify and monitor analytes, previously requiring invasive or expensive lab tests.
• The first product application, a non-invasive glucose monitor, aims to provide accessible and affordable real-time information on blood glucose levels.

Negatives

• The adjournment of the Special Meeting of Stockholders suggests that the company may not have secured sufficient votes or engagement from stockholders by the original deadline.

Risks

• Fluctuations in the market price of Bitcoin and associated impairment charges if the market price falls below the company's carrying value.
• Uncertainties and effects related to ongoing volatility in interest rates.
• The company's ability to achieve and maintain profitability in the future.
• The timing to consummate the proposed transaction (referring to the proposals being voted on).
• The risk that a condition for closing the proposed transaction may not be satisfied or that the closing might not occur.
• The impact of the regulatory environment on the company's business and complexities with compliance, including changes in securities laws or other regulations.
• Changes in the accounting treatment relating to the company's Bitcoin holdings.
• The company's ability to respond to general economic conditions.
• The company's ability to manage its growth effectively and its expectations regarding the development and expansion of its business.
• The company's ability to access sources of capital, including debt financing and other sources, to finance operations and growth.
• Other risks and uncertainties detailed in the company's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and other SEC filings.

Future Outlook

The company's first application of its spectroscopy technology will be a non-invasive glucose monitor, which will require U.S. Food and Drug Administration (FDA) clearance before its market introduction. Other products based on the company's technology may not require such FDA approval.

Management Comments

• "The Board of Directors recommends any stockholders as of the record date of June 20, 2025, who have not yet voted their shares for the Special Meeting, to cast their vote FOR each proposal, now."
• "For stockholders who have not yet cast their votes, we urge them to vote their shares now, so they can be tabulated prior to the reconvened Special Meeting."

Industry Context

Know Labs operates in the rapidly evolving non-invasive health monitoring sector, aiming to disrupt traditional invasive diagnostic methods. The company's focus on developing a non-invasive glucose monitor aligns with a significant and growing market need for convenient, continuous glucose monitoring, driven by the increasing prevalence of diabetes and the demand for personal health management tools. The necessity for FDA clearance for its primary product underscores the stringent regulatory environment for medical devices in this space, which can be a significant barrier to entry but also a validation of product efficacy and safety.

Corporate Governance

Stakeholder Impact

• Shareholders: Provided additional time to vote on important proposals; urged to cast votes FOR the proposals.
• Customers/Patients: Potential future benefit from non-invasive health monitoring solutions, particularly the glucose monitor, pending FDA clearance.

Next Steps

• Stockholders are urged to vote on the proposals before the Internet and telephone voting deadline of July 30, 2025, 11:59 p.m. ET.
• The reconvened Special Meeting of Stockholders will take place on July 31, 2025, at 1:30 p.m. PT.
• Future introduction of the non-invasive glucose monitor product is contingent upon receiving U.S. Food and Drug Administration (FDA) clearance.

Key Dates

Recommendation

The filing is primarily procedural, announcing the adjournment of a special stockholder meeting. It does not contain new financial results or significant operational updates that would warrant a strong buy or sell recommendation. The company's core business in non-invasive health monitoring is interesting, but the filing provides no new information on its progress or market reception. The risks mentioned are general forward-looking statements. Therefore, a 'hold' recommendation is appropriate as investors should await more substantive updates on product development, FDA clearance, and financial performance.

Keywords

Know Labs, KNW, SEC filing, DEFA14A, proxy statement, special meeting, stockholder vote, non-invasive health monitoring, glucose monitor, spectroscopy, FDA clearance, corporate governance, investor relations